Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410867 | 0.87 | PIK3CG (0.38) | PIK3CGKDM4EGAA | |
| SCHEMBL15662749 | 0.79 | PIK3CG (0.41) | PIK3CGKDM4EGAA | |
| SCHEMBL7271827 | 0.79 | PIK3CG (0.44) | PIK3CGKDM4EGAA | |
| SCHEMBL12410858 | 0.77 | PIK3CG (0.40) | PIK3CGRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL28917520 | 0.77 | PIK3CG (0.40) | PIK3CGKDM4EGAA | |
| SCHEMBL30281806 | 0.77 | PIK3CG (0.40) | PIK3CGALDH1A1KDM4EGAA | |
| SCHEMBL25259423 | 0.76 | PIK3CG (0.39) | PIK3CGKDM4EGAA | |
| Potassium Ion SCHEMBL22659395 | 0.76 | PIK3CG (0.39) | PIK3CGKDM4EGAA | |
| Hydrochloric Acid SCHEMBL30484796 | 0.76 | PIK3CG (0.39) | PIK3CGRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9608841 | 0.75 | DPP4 (0.36) | HDAC4RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PIK3CG 1174/4885HDAC4 909/4885RAB9A 1870/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PIK3CG 1174/4885HDAC4 909/4885RAB9A 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.